CLINICAL_TRIALS
trial_result
· 2021-11-10
Clinical Trial Update: V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002) [Phase 2]
Summary
Phase 2 trial update for V160 regimens in CMV-seronegative healthy females; results completed and posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Cytomegalovirus (CMV) Infections | Phase 2 | Status: COMPLETED | Results posted: 2021-11-10